OzempicvsWegovy
Both are GLP-1 receptor agonist • Side-by-side comparison
Ozempic vs Wegovy: Overview
Ozempic and Wegovy are both brand-name medications containing semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. Despite sharing the same active ingredient, they are FDA-approved for different conditions and come in different doses. Ozempic was approved in 2017 for type 2 diabetes management and cardiovascular risk reduction, while Wegovy received FDA approval in 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Both medications work by mimicking the GLP-1 hormone to regulate blood sugar, slow gastric emptying, and reduce appetite — but Wegovy is prescribed at a higher maximum dose (2.4 mg weekly) compared to Ozempic (2 mg weekly), which contributes to its greater average weight loss outcomes in clinical trials.
Key Facts at a Glance
- ✓Same active ingredient (semaglutide) — different FDA-approved uses
- ✓Wegovy approved for weight loss; Ozempic approved for type 2 diabetes
- ✓Wegovy max dose is 2.4 mg/week; Ozempic max dose is 2 mg/week
- ✓Clinical trials show Wegovy produces ~15% average body weight loss vs ~6% for Ozempic
- ✓Both are weekly subcutaneous injections with similar side effect profiles
- ✓Ozempic is often covered by insurance for diabetes; Wegovy coverage varies
Ozempic
Drug AUsed For
- ✓ Type 2 diabetes
Wegovy
Drug BUsed For
- ✓ Weight loss
Key Differences
Which Should You Choose?
If your primary goal is weight loss and you do not have type 2 diabetes, Wegovy is the FDA-approved choice. If you have type 2 diabetes and also want to benefit from weight loss effects, Ozempic is typically prescribed and may have better insurance coverage. Some doctors prescribe Ozempic off-label for weight loss when Wegovy is unavailable or unaffordable. Always discuss your specific health goals with your doctor before choosing between these medications.